[go: up one dir, main page]

CL2018001714A1 - Reguladores del cftr y métodos para su uso - Google Patents

Reguladores del cftr y métodos para su uso

Info

Publication number
CL2018001714A1
CL2018001714A1 CL2018001714A CL2018001714A CL2018001714A1 CL 2018001714 A1 CL2018001714 A1 CL 2018001714A1 CL 2018001714 A CL2018001714 A CL 2018001714A CL 2018001714 A CL2018001714 A CL 2018001714A CL 2018001714 A1 CL2018001714 A1 CL 2018001714A1
Authority
CL
Chile
Prior art keywords
methods
cfr
regulators
disorders
cftr
Prior art date
Application number
CL2018001714A
Other languages
English (en)
Inventor
Alan Verkman
Marc H Levin
Onur Cil
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of CL2018001714A1 publication Critical patent/CL2018001714A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Prostheses (AREA)

Abstract

EN EL PRESENTE DOCUMENTO SE PROPORCIONAN COMPUESTOS QUE ACTIVAN EL CFTR Y MÉTODOS PARA TRATAR EL ESTREÑIMIENTO, LOS TRASTORNOS DEL OJO SECO U OTRAS ENFERMEDADES Y TRASTORNOS.
CL2018001714A 2015-12-24 2018-06-21 Reguladores del cftr y métodos para su uso CL2018001714A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562387591P 2015-12-24 2015-12-24

Publications (1)

Publication Number Publication Date
CL2018001714A1 true CL2018001714A1 (es) 2018-10-26

Family

ID=59091233

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001714A CL2018001714A1 (es) 2015-12-24 2018-06-21 Reguladores del cftr y métodos para su uso

Country Status (16)

Country Link
US (2) US20190031630A1 (es)
EP (1) EP3394083B9 (es)
JP (1) JP6894902B2 (es)
KR (1) KR102723194B1 (es)
CN (1) CN108699107B (es)
AU (2) AU2016377782B2 (es)
BR (1) BR112018012927A2 (es)
CL (1) CL2018001714A1 (es)
CO (1) CO2018007239A2 (es)
ES (1) ES2901002T3 (es)
IL (2) IL299924B2 (es)
PL (1) PL3394083T3 (es)
PT (1) PT3394083T (es)
RU (1) RU2742934C2 (es)
WO (1) WO2017112947A1 (es)
ZA (1) ZA201804228B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10604492B2 (en) 2015-12-24 2020-03-31 The Regents Of The Universtiy Of California CFTR regulators and methods of use thereof
IT201700085714A1 (it) * 2017-07-26 2019-01-26 Luigi Maiuri Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine.
US11839616B2 (en) 2017-08-24 2023-12-12 The Regents Of The University Of California Ocular pharmaceutical compositions
FR3096890B1 (fr) * 2019-06-07 2021-05-14 H4 Orphan Pharma Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique.
US20220071549A1 (en) * 2020-09-08 2022-03-10 The Regents Of The University Of California Apparatus, systems and methods of use for ocular surface potential difference measurement
WO2022084741A1 (en) 2020-10-23 2022-04-28 Ildong Pharmaceutical Co., Ltd. Cftr modulator compounds, compositions, and uses thereof
CN113527225B (zh) * 2021-07-15 2022-11-18 南昌大学 一种丙烯酰噻二唑衍生物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509923A (ja) 1998-03-31 2002-04-02 ワーナー−ランバート・カンパニー Ｘａ因子およびトロンビンのようなセリンプロテアーゼ阻害剤としてのキノキサリノン
NZ538809A (en) * 2002-09-30 2008-06-30 Univ California Thiazolidinone cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US7977322B2 (en) * 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2005075435A1 (en) * 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US20090105240A1 (en) * 2007-10-17 2009-04-23 Tomas Mustelin Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
EP2247580B1 (en) 2008-03-05 2015-07-08 Merck Patent GmbH Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
US8314239B2 (en) 2008-10-23 2012-11-20 Vertex Pharmaceutical Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2010073011A2 (en) * 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
TWI450891B (zh) * 2010-12-29 2014-09-01 Dev Center Biotechnology 新穎微管蛋白抑制劑
WO2015138909A1 (en) * 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
US10174014B2 (en) 2014-06-19 2019-01-08 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity

Also Published As

Publication number Publication date
CO2018007239A2 (es) 2018-07-19
IL299924B1 (en) 2024-09-01
ZA201804228B (en) 2020-09-30
JP6894902B2 (ja) 2021-06-30
KR102723194B1 (ko) 2024-10-28
EP3394083B9 (en) 2022-04-27
EP3394083A4 (en) 2019-09-04
WO2017112947A1 (en) 2017-06-29
IL260210A (en) 2018-07-31
PL3394083T3 (pl) 2022-01-17
EP3394083A1 (en) 2018-10-31
NZ743720A (en) 2024-08-30
JP2018538354A (ja) 2018-12-27
BR112018012927A2 (en) 2018-12-11
IL260210B2 (en) 2023-06-01
KR20180101415A (ko) 2018-09-12
RU2018126959A (ru) 2020-01-24
EP3394083B1 (en) 2021-09-01
ES2901002T3 (es) 2022-03-21
US11192869B2 (en) 2021-12-07
US20200140402A1 (en) 2020-05-07
IL299924A (en) 2023-03-01
AU2016377782A1 (en) 2018-07-12
RU2018126959A3 (es) 2020-08-20
IL299924B2 (en) 2025-01-01
AU2021257948A1 (en) 2021-11-25
US20190031630A1 (en) 2019-01-31
AU2021257948B2 (en) 2023-11-30
CN108699107B (zh) 2022-05-10
RU2742934C2 (ru) 2021-02-11
PT3394083T (pt) 2021-12-07
AU2016377782B2 (en) 2021-07-29
ES2901002T9 (es) 2022-06-20
CN108699107A (zh) 2018-10-23
CA3009531A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
CL2018001714A1 (es) Reguladores del cftr y métodos para su uso
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
ECSP18094857A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
ECSP17031725A (es) Receptores quiméricos de anitígeno anti-clon y métodos de uso
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
BR112017006664A2 (pt) terapias de combinação
CL2015002855A1 (es) Derivados de oxopiridina sustituida.
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
BR112018012138A2 (pt) moléculas de anticorpo para pd-1 e usos das mesmas
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
CO2018007237A2 (es) Reguladores del cftr y métodos para su uso
LT3472153T (lt) Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme
CR20170230A (es) Anticuerpos anti-cd79b y métodos de uso
BR112016029864A2 (pt) métodos e dispositivos para tratamento de desordens oculares posteriores.
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
TR201900124T4 (tr) Dispersiyon Reçineleri
MX389741B (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas.
CL2016002257A1 (es) Anticuerpos anti-mcam y métodos de uso asociados
CL2017001046A1 (es) Inhibidoes del bromodominio
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
BR112016026544A2 (pt) métodos para inibir a necroptose
DK3388064T3 (da) 2,4-thiazolidindionderivater i behandling af forstyrrelse i centralnervesystemet
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas